scholarly journals Tumor Pain, CTCAE 5.0

2020 ◽  
Author(s):  
Keyword(s):  
Tumor Pain

Resolution of tumor pain with EMLA® Cream: A case report

1995 ◽  
Vol 12 (1) ◽  
pp. 19-21
Author(s):  
Mary B. Stegman ◽  
Cheryl A. Stoukides
Keyword(s):  
Case Report ◽  
Tumor Pain

T162 A NOVEL, NON-VASCULAR ROLE FOR VEGF IN CANCER: VEGFR1 EXPRESSED ON SENSORY NERVES MEDIATES TUMOR PAIN

2011 ◽  
Vol 5 (S1) ◽  
pp. 33-33
Author(s):  
D. Selvaraj ◽  
M. Kurejova ◽  
V. Gangadharan ◽  
S. Stösser ◽  
C. Michalski ◽  
...  
Keyword(s):  
Sensory Nerves ◽  
Tumor Pain

Cancer and tumor pain

2009 ◽  
pp. 151-161
Author(s):  
Michael Walta ◽  
Stephen H. Thomas
Keyword(s):  
Tumor Pain

scholarly journals Acute Tumor Pain in Patients With Head and Neck Cancer Treated With Vinorelbine

1996 ◽  
Vol 88 (21) ◽  
pp. 1593-1593 ◽  
Author(s):  
G.-V. KORNEK ◽  
H. KORNFEHL ◽  
M. HEJNA ◽  
M. RADERER ◽  
S. ZOCHBAUER ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumor Pain

scholarly journals Tumor Pain

2020 ◽  
Author(s):  
Keyword(s):  
Tumor Pain

Tumor Pain Treatment

2003 ◽  
Vol 38 (6) ◽  
pp. 403-437 ◽  
Author(s):  
H. Ohnesorge ◽  
D. Siebrecht ◽  
M. Gleim
Keyword(s):  
Pain Treatment ◽  
Tumor Pain

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

2002 ◽  
Vol 20 (19) ◽  
pp. 4074-4082 ◽  
Author(s):  
Antoinette R. Tan ◽  
Donna Headlee ◽  
Richard Messmann ◽  
Edward A. Sausville ◽  
Susan G. Arbuck ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Single Agent ◽  
Optimal Schedule ◽  
Maximum Tolerated Dose ◽  
Chemotherapeutic Agents ◽  
Cyclin Dependent Kinase ◽  
Cyclin Dependent Kinases ◽  
Cyclin Dependent Kinase Inhibitor ◽  
Tumor Pain ◽  
Micromolar Range

PURPOSE: To define the maximum-tolerated dose (MTD), dose-limiting toxicity, and pharmacokinetics of the cyclin-dependent kinase inhibitor flavopiridol administered as a daily 1-hour infusion every 3 weeks. PATIENTS AND METHODS: Fifty-five patients with advanced neoplasms were treated with flavopiridol at doses of 12, 17, 24, 30, 37.5, and 52.5 mg/m2/d for 5 days; doses of 50 and 62.5 mg/m2/d for 3 days; and doses of 62.5 and 78 mg/m2/d for 1 day. Plasma sampling was performed to characterize the pharmacokinetics of flavopiridol with these schedules. RESULTS: Dose-limiting neutropenia developed at doses ≥ 52.5 mg/m2/d. Nonhematologic toxicities included nausea, vomiting, diarrhea, hypotension, and a proinflammatory syndrome characterized by anorexia, fatigue, fever, and tumor pain. The median peak concentrations of flavopiridol achieved at the MTDs on the 5-day, 3-day, and 1-day schedule were 1.7 μmol/L (range, 1.3 to 4.2 μmol/L), 3.2 μmol/L (range, 1.7 to 4.8 μmol/L), and 3.9 μmol/L (1.8 to 5.1 μmol/L), respectively. Twelve patients had stable disease for ≥ 3 months, with a median duration of 6 months (range, 3 to 11 months). CONCLUSION: The recommended phase II doses of flavopiridol as a 1-hour infusion are 37.5 mg/m2/d for 5 days, 50 mg/m2/d for 3 days, and 62.5 mg/m2/d for 1 day. Flavopiridol as a daily 1-hour infusion can be safely administered and can achieve concentrations in the micromolar range, sufficient to inhibit cyclin-dependent kinases in preclinical models. Further studies to determine the optimal schedule of flavopiridol as a single agent and in combination with chemotherapeutic agents are underway.

Treatment of Vinorelbine-Associated Tumor Pain

2001 ◽  
Vol 24 (4) ◽  
pp. 414-415 ◽  
Author(s):  
Teresa D. Long ◽  
Robert K. Twillman ◽  
Teresa A. Cathers-Schiffman ◽  
Teri OʼDonnell
Keyword(s):  
Tumor Pain
Sign in / Sign up

Export Citation Format

Share Document